The framework balances two equal goals: - Preventing organ dysfunction in those without complications by targeting fat mass accumulation - Reversing organ dysfunction in patients with complications such as type 2 diabetes, cardiovascular disease, MASLD, heart failure, or osteoarthritis This approach positions obesity treatment as disease modification, emphasizing protection of the heart, liver, pancreas, joints, and lungs beyond weight reduction alone EASO Framework: #EASO #Tirzepatide #Semaglutide #GLP1RAs #Getzpharma To view or add a comment, sign in Chronic kidney disease (CKD) is highly heterogeneous with different etiologies and mechanisms believed to underlie diabetic kidney disease (DKD), glomerulonephritis (GN), and hypertensive nephropathy (HTN)
Both rose immediately after LPS administration to the maximum at 0.5 h pi and dropped afterwards significantly to a nadir at 9 h pi
Does GLP-1 reduce alcohol cravings
Methylmalonyl-CoA Mutase: B12 participates in the conversion of methylmalonyl-CoA to succinyl-CoA, linking certain fatty acid and amino acid degradation pathways into the tricarboxylic acid (TCA) cycle
